Top anti-rheumatic products based on global revenue in 2017 and 2024 (in million U.S. dollars)

Top worldwide anti-rheumatics by revenue 2017 and 2024 This statistic displays the top anti-rheumatics worldwide by revenue in 2017 and a projection for 2024. Enbrel, a drug developed by Pfizer, Amgen, and Takeda, is expected to generate some four billion U.S. dollars in revenue in 2024. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs.
Anti-rheumatic products

Some of the top anti-rheumatic products in the world include J&J, Merck & Co., and Mitsubishi’s Remicade, which generated 8.1 billion U.S. dollars in revenue in 2016 and is expected to decrease to 2.7 billion U.S. dollars by 2022. This drug accounted for over 15 percent of the global market in 2016. Remicade is a trade name for infliximab, an antibody used in the treatment of autoimmune diseases. It is marketed under the name Remicade in the United States and cost between 19,000 and 22,000 per year for patients. Merck & Co. markets this product as Schering-Plough in other regions. Merck & Co. generated 1.7 billion U.S. dollars in their oncology segment in 2016. Remicade works by targeting tumor necrosis factor alpha and inhibiting its activity, but unlike similar rheumatic products like Humira, it is a monoclonal antibody.

Rheumatic diseases include conditions that affect the joints and connective tissue. Arthritis and gout are some of the more common types of this autoimmune disease. Osteoarthritis is one of the most common types of arthritis in the United States, it is characterized by the destruction of cartilage and bone. In Canada, 4.8 million adults over 15 reported that they had been diagnosed with arthritis.
Show more
Loading statistic...
Product (Company)20172024
Humira (AbbVie, Eisai)18,92215,233
Enbrel (Pfizer, Amgen, Takeda)8,2414,072
Simponi (J&J, Merck)2,6522,845
Otezla (Celgene)1,2792,621
Upadacitinib (AbbVie)-2,570
Product (Company)20172024
Humira (AbbVie, Eisai)18,92215,233
Enbrel (Pfizer, Amgen, Takeda)8,2414,072
Simponi (J&J, Merck)2,6522,845
Otezla (Celgene)1,2792,621
Upadacitinib (AbbVie)-2,570
Download Settings Share
Chart type
Datalabels
Share on Social Media
HTML code to embed chart as PNG (FAQ)
Download started
Please be patient - this may take a moment
Description Source More information
This statistic displays the top anti-rheumatics worldwide by revenue in 2017 and a projection for 2024. Enbrel, a drug developed by Pfizer, Amgen, and Takeda, is expected to generate some four billion U.S. dollars in revenue in 2024. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs.
Anti-rheumatic products

Some of the top anti-rheumatic products in the world include J&J, Merck & Co., and Mitsubishi’s Remicade, which generated 8.1 billion U.S. dollars in revenue in 2016 and is expected to decrease to 2.7 billion U.S. dollars by 2022. This drug accounted for over 15 percent of the global market in 2016. Remicade is a trade name for infliximab, an antibody used in the treatment of autoimmune diseases. It is marketed under the name Remicade in the United States and cost between 19,000 and 22,000 per year for patients. Merck & Co. markets this product as Schering-Plough in other regions. Merck & Co. generated 1.7 billion U.S. dollars in their oncology segment in 2016. Remicade works by targeting tumor necrosis factor alpha and inhibiting its activity, but unlike similar rheumatic products like Humira, it is a monoclonal antibody.

Rheumatic diseases include conditions that affect the joints and connective tissue. Arthritis and gout are some of the more common types of this autoimmune disease. Osteoarthritis is one of the most common types of arthritis in the United States, it is characterized by the destruction of cartilage and bone. In Canada, 4.8 million adults over 15 reported that they had been diagnosed with arthritis.
Show more
Release date
June 2018
Region
Worldwide
Survey time period
as of May 2018
Supplementary notes
* Projected.
Open this statistic in...

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Basic Account

Get to know the platform

You only have access to basic statistics.

Register for free

Premium Account

Your perfect start with Statista

  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account

Full access

Corporate solution including all features.

Send request

* All products require an annual contract.
   Prices do not include sales tax
   (New York residents only).
Leading companies trust Statista:

Related Studies: Available to Download in PDF or PPTX Format

Pharmaceutical brands: Enbrel (Amgen/Pfizer)

All Information
in one Presentation

Pharmaceutical brands: Enbrel (Amgen/Pfizer)

Everything On "Pharmaceutical brands: Enbrel (Amgen/Pfizer)" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Top pharmaceutical drugs"

  • Global overview
  • Select therapy classes - global
The most important statistics
  • U.S. overview
The most important statistics
  • Select therapy classes - U.S.
Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.

5 News

We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.